FN1 and acute myeloid leukemia: Although fibronectin did not lead to a significant survival prolongation in BCR-ABL1+ B-ALL or MLL-AF9+ AML, it is likely that this may have been due to suboptimal dosing and timing of the administration of fibronectin, whose high purchasing costs were prohibitive of further exploration in this study.